Device Trial Radar · NCT03284619
First-In Man (FIM) Study MR-Linac
Last checked: Nov 20, 2026Latest source record: Mar 29, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
5
Actual
Start
Apr 1, 2017
Primary completion
Jul 11, 2017
Study completion Sep 8, 2017
Sponsor
- Lead sponsor
- Nucletron Operations BVNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Factory CRO for Medical Devices B.V.
- First posted
- Sep 15, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Investigational device is the Magnetic resonance imager linear accelerator. Five (5) patients with bone metastases will be treated with palliative intention in this study. The goal is to confirm the pre-clinically demonstrated technical accuracy and safety of the newly developed MR-Linac in the clinical setting.
Conditions
- Bone Metastases
Interventions
Magnetic resonance imager linear acceleratorDevice
The MR linear accelerator (MRL) integrates a radiotherapy accelerator and a diagnostic quality 1.5T MRI, enabling soft-tissue visualization during the actual radiation delivery for improved targeting. This enables on-line treatment optimization for precise radiation delivery. Better visualization of the tumour targets and the surrounding healthy tissues, at the exact moment of treatment, makes it possible to adapt the dose to the actual anatomy while optimally sparing normal tissues.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of the treatment system (a dose distribution accuracy ≤ 5% will be considered acceptable). Incidence of acute toxicity (CTCAE grade 2 are higher) and incidence of Serious (unexpected) Adverse Events will be measured.Time frame: During treatment (Day 0). For patient safety patients will be contacted at day 1, week 2 and week 12 after treatment.
- Geometrical accuracy of targeting by online MR imagingTime frame: During treatment (day 0)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Medical Centre Utrecht
Utrecht, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.